# Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)

> **NCT00571753** · PHASE3 · TERMINATED · sponsor: **University of Cologne** · enrollment: 900 (estimated)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** isoniazid
- **DRUG:** isoniazid

## Key facts

- **NCT ID:** NCT00571753
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2011-12
- **Final completion:** 2012-02
- **Target enrollment:** 900 (ESTIMATED)
- **Why stopped:** Enrolling participants has halted prematurely due to a low recruitment rate.
- **Last updated:** 2011-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00571753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00571753, "Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00571753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*